Furthermore, pre-clinical findings showed that this tracer monitored early response to T-DM1 therapy of HER2-positive breast cancer xenograft-bearing mice and allowed precise detection of changes in tumor volume [33]. This evidence concerns the gene ERBB2 and neoplasm.